NCT04023331 2025-09-16
67Cu-SARTATEā¢ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma
Clarity Pharmaceuticals Ltd
Phase 1/2 Terminated
Clinical Trials
4 trialsNCT04438304 2025-02-12
A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)
Clarity Pharmaceuticals Ltd
Phase 2 Completed
NCT04440956 2020-06-22
An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours
Clarity Pharmaceuticals Ltd
Phase EARLY_PHASE1 Completed
NCT03936426 2020-04-20
Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATEā¢
Clarity Pharmaceuticals Ltd
Phase 1/2 Completed